353 related articles for article (PubMed ID: 19369348)
41. Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo.
Porgador A; Staats HF; Faiola B; Gilboa E; Palker TJ
J Immunol; 1997 Jan; 158(2):834-41. PubMed ID: 8993001
[TBL] [Abstract][Full Text] [Related]
42. Reprogramming Immune Response With Capsid-Optimized AAV6 Vectors for Immunotherapy of Cancer.
Pandya M; Britt K; Hoffman B; Ling C; Aslanidi GV
J Immunother; 2015 Sep; 38(7):292-8. PubMed ID: 26261893
[TBL] [Abstract][Full Text] [Related]
43. Pre-existing immunity to adeno-associated virus (AAV)2 limits transgene expression following intracerebral AAV2-based gene delivery in a 6-hydroxydopamine model of Parkinson's disease.
Janelidze S; Nordström U; Kügler S; Brundin P
J Gene Med; 2014; 16(9-10):300-8. PubMed ID: 25303717
[TBL] [Abstract][Full Text] [Related]
44. Relevance of Assembly-Activating Protein for Adeno-associated Virus Vector Production and Capsid Protein Stability in Mammalian and Insect Cells.
Grosse S; Penaud-Budloo M; Herrmann AK; Börner K; Fakhiri J; Laketa V; Krämer C; Wiedtke E; Gunkel M; Ménard L; Ayuso E; Grimm D
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768875
[TBL] [Abstract][Full Text] [Related]
45. Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential.
Li Q; Miller R; Han PY; Pang J; Dinculescu A; Chiodo V; Hauswirth WW
Mol Vis; 2008 Sep; 14():1760-9. PubMed ID: 18836574
[TBL] [Abstract][Full Text] [Related]
46. Targeting photoreceptors via intravitreal delivery using novel, capsid-mutated AAV vectors.
Kay CN; Ryals RC; Aslanidi GV; Min SH; Ruan Q; Sun J; Dyka FM; Kasuga D; Ayala AE; Van Vliet K; Agbandje-McKenna M; Hauswirth WW; Boye SL; Boye SE
PLoS One; 2013; 8(4):e62097. PubMed ID: 23637972
[TBL] [Abstract][Full Text] [Related]
47. Genetically engineered fibroblasts with antigen-presenting capability: efficient induction of an antigen-specific cytotoxic T-lymphocyte response and protection against tumor development in vivo.
Kim TS; Chung SW; Kim SH; Kang BY; Hwang SY; Lee JW
Cancer Gene Ther; 2000 Jun; 7(6):861-9. PubMed ID: 10880016
[TBL] [Abstract][Full Text] [Related]
48. Antigen-Specific In Vivo Killing Assay.
Chaoul N; Dadaglio G
Methods Mol Biol; 2021; 2325():55-64. PubMed ID: 34053050
[TBL] [Abstract][Full Text] [Related]
49. The cytotoxic T lymphocyte response against a protein antigen does not decrease the antibody response to that antigen although antigen-pulsed B cells can be targets.
Wang W; Golding B
Immunol Lett; 2005 Sep; 100(2):195-201. PubMed ID: 15916814
[TBL] [Abstract][Full Text] [Related]
50. Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein.
Mori S; Wang L; Takeuchi T; Kanda T
Virology; 2004 Dec; 330(2):375-83. PubMed ID: 15567432
[TBL] [Abstract][Full Text] [Related]
51. Cytotoxic T cell responses to DNA vaccination: dependence on antigen presentation via class II MHC.
Maecker HT; Umetsu DT; DeKruyff RH; Levy S
J Immunol; 1998 Dec; 161(12):6532-6. PubMed ID: 9862678
[TBL] [Abstract][Full Text] [Related]
52. Double-stranded RNA innate immune response activation from long-term adeno-associated virus vector transduction.
Shao W; Earley LF; Chai Z; Chen X; Sun J; He T; Deng M; Hirsch ML; Ting J; Samulski RJ; Li C
JCI Insight; 2018 Jun; 3(12):. PubMed ID: 29925692
[TBL] [Abstract][Full Text] [Related]
53. Intradermal injections of polyarginine-containing immunogenic antigens preferentially elicit Tc1 and Th1 activation and antitumour immunity.
Mitsui H; Okamoto T; Kanzaki M; Inozume T; Shibagaki N; Shimada S
Br J Dermatol; 2010 Jan; 162(1):29-41. PubMed ID: 19863514
[TBL] [Abstract][Full Text] [Related]
54. Generation of tumor-specific cytotoxic T lymphocyte and prolongation of the survival of tumor-bearing mice using interleukin-18-secreting fibroblasts loaded with an epitope peptide.
Chung SW; Cohen EP; Kim TS
Vaccine; 2004 Jun; 22(20):2547-57. PubMed ID: 15193380
[TBL] [Abstract][Full Text] [Related]
55. The Effect of CpG Sequences on Capsid-Specific CD8
Xiang Z; Kurupati RK; Li Y; Kuranda K; Zhou X; Mingozzi F; High KA; Ertl HCJ
Mol Ther; 2020 Mar; 28(3):771-783. PubMed ID: 31839483
[TBL] [Abstract][Full Text] [Related]
56. An Immune-Competent Murine Model to Study Elimination of AAV-Transduced Hepatocytes by Capsid-Specific CD8
Palaschak B; Marsic D; Herzog RW; Zolotukhin S; Markusic DM
Mol Ther Methods Clin Dev; 2017 Jun; 5():142-152. PubMed ID: 28480313
[TBL] [Abstract][Full Text] [Related]
57. Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or -2 serotypes for widespread gene delivery to the neonatal mouse brain.
Broekman ML; Comer LA; Hyman BT; Sena-Esteves M
Neuroscience; 2006; 138(2):501-10. PubMed ID: 16414198
[TBL] [Abstract][Full Text] [Related]
58. An immunodominant cytotoxic T cell epitope on the VP7 rotavirus protein overlaps the H2 signal peptide.
Franco MA; Prieto I; Labbé M; Poncet D; Borras-Cuesta F; Cohen J
J Gen Virol; 1993 Dec; 74 ( Pt 12)():2579-86. PubMed ID: 8277264
[TBL] [Abstract][Full Text] [Related]
59. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism.
Wu P; Xiao W; Conlon T; Hughes J; Agbandje-McKenna M; Ferkol T; Flotte T; Muzyczka N
J Virol; 2000 Sep; 74(18):8635-47. PubMed ID: 10954565
[TBL] [Abstract][Full Text] [Related]
60. Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid.
Vandenberghe LH; Wang L; Somanathan S; Zhi Y; Figueredo J; Calcedo R; Sanmiguel J; Desai RA; Chen CS; Johnston J; Grant RL; Gao G; Wilson JM
Nat Med; 2006 Aug; 12(8):967-71. PubMed ID: 16845388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
